NEWS

대웅제약 자회사 아이엔테라퓨틱스, 디어젠과 난청치료제 개발

2020.11.19

아이엔테라퓨틱스(대표 박종덕)는 디어젠(대표 강길수)의 AI플랫폼을 활용해 난청치료제 신약물질 발굴에 돌입했다고 17일 밝혔다. 아이엔테라퓨틱스는 대웅제약에서 분사된 신약개발 전문 자회사다. Read More

NEWS

[Press Release] DEARGEN and SKChemical announce strategic collaboration to drug discovery using AI platform

2020.11.19

we announce our partnership with SK Chemical to co-develop AI-based new drugs. As part of this partnership, SKChemical and Deargen will conduct joint researches on “drug repositioning” and “de novo drug design.” Read More

NEWS

디어젠, pre-시리즈A 30억 유치.. ‘배영철 CBO 영입’

2020.11.03

인공지능(AI) 기반 신약개발 전문기업인 디어젠(Deargen)이 pre-시리즈A로 30억원 규모의 투자유치를 마쳤다고 26일 밝혔다. Read More

NEWS

아밀로이드솔루션, AI 디어젠 인수.. ‘AD 신약개발 속도’

2020.11.03

알츠하이머병 치료제 신약개발 기업인 아밀로이드솔루션(Amyloid Solution)이 인공지능(AI) 기반 신약개발 전문기업인 디어젠(Deargen)을 인수했다. Read More

NEWS

[Press Release] Optipharm and Deargen start developing vaccine for liver cancer treatment using AI

2020.08.25

Optipharm and Deargen, Introduced AI to find antigens (epitopes) that cause immune responses to liver cancer cells. Read More

NEWS

[Event] DEARGEN, in ‘KOREA Pharm and Bio 2020’ Fair

2020.08.13

DEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Especially for the case of COVID-19 treatment prediction using AI. Read More

NEWS

Five Companies Using AI to Fight Coronavirus

2020.03.23

Deep learning models predict old and new drugs that might successfully treat COVID-19. Read More

NEWS

Deargen Predicted Potential Antivirals for The Novel Coronavirus Infection using AI

2020.02.07

Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the deep-learning technology based AI model MT-DTI. The work is published on the BioRxiv. Read More

TECH REVIEW

MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds

2020.02.05

Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12. Read More

PROJECTS

First-in Class Drug Targeting DDT2 (Code Name) Transcription Factor for Primary Cancers

2019.09.03

We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS. Read More

TECH REVIEW

A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.

2019.08.14

Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR). Read More

NEWS

[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.

2019.08.12

Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”. Read More

PROJECTS

Treatment of Sarcopenia using Small Molecules

2019.08.05

Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules. Read More

PROJECTS

Undruggable to Degradable with AI

2019.08.05

PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein. Read More

PROJECTS

Colorectal Cancer, MERTK, and Small molecular

2019.08.05

The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors. Read More

PROJECTS

ALS (Lou Gehrig), a Challenge to Radical Cure

2019.08.05

ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig. Read More

NEWS

[Press Release] Deargen, Signed a Strategic Technology Agreement with Uppthera for Discovering PROTAC Drug Candidates using AI.

2019.08.02

Uppthera Inc. that is a domestic PROTAC-based drug development company joined hands with Deargen Inc. that is an AI-based drug development platform company. It is going to discover PROTAC drug candidates using artificial intelligence technology. On the 7th, Uppthera Inc. and Deargen Inc. recently announced that they have signed a strategic technology partnership agreement on the AI-based PROTAC drug development. Read More

TECH REVIEW

Prediction of origin of cancer by deep-learning analysis using pan-cancer transcriptome

2019.07.22

We introduce DEARGEN’s research results on the model that predicts the primary cancer sites (cancer metastasis prediction) through the gene expression profile (GEP). Read More

TECH REVIEW

CWx (Cascaded Wx): Technology for Prognosis Biomarker Discovery

2019.07.19

Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis. The research achievements has been published in the journal Frontiers in Genetics. Read More

TECH REVIEW

WX: Technology for Novel Biomarker Discovery

2019.07.19

Deargen has announced research results on an AI technology Wx that can discover novel biomarkers. Research achievements are being published in the journal of the Nature Scientific Report, and two inventions related to these have been patented. Read More

NEWS

Deargen, Selected for the TIPS Program with Genomic Data Analysis Service

2018.11.15

Deargen was selected for the TIPS program, so it will receive a total of $600,000 in R & D expenses from the operator Medytox Venture Investment. Read More

NEWS

Genomic Data Analysis Platform ‘DearTRANS’ Beta Service Launch

2018.07.06

Deargen launches a beta service of ‘DearTRANS’ that is a cloud-based genomic big data analysis platform that the world’s first artificial intelligence technologies are applied. Read More

NEWS

The Challenge to Conquer Cancer, Prognostic Prediction Analysis of Lung Cancer Using AI

2017.04.17

Deargen has been selected for the 2017 National Program for Cancer Control that is hosted by the Ministry of Health and Welfare and the National Cancer Center. Deargen will develop an integrated prognostic analysis model of lung cancer using artificial intelligence by collaboration with St. Mary’s Hospital and Dankook University. Read More

NEWS

Deargen was selected as Top Performers of the NCI-CPTAC DREAM Challenge

2017.01.20

Deargen was selected as a Top Performer of the NCI-CPTAC DREAM Proteogenomics Computational Challenges that is international Challenges for cancer proteome prediction. Details of the challenge will be published in the Nature Method. Read More

NEWS

Deargen, Won at ILSVRC 2016 (ImageNet Large Scale Visual Recognition Challenge)

2016.12.23

Deargen was voted in the top 10 in the world at the ‘ImageNet Large Scale Visual Recognition Challenge (ILSVRC) 2016’, the Image Recognition International Competition. The error rate of 3.5% in recognition (the 4% human error rate) has attained, which shows a much improved result compared to the error rate of Microsoft Research Lab that is a last year’s winner. Read More